Home > News > Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
January 20th, 2003
Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
Targesome Inc., co-founded by Drs. King Li and Mark Bednarski in late 1999, is developing nanoparticles that can be used for drug delivery. Any drug can be attached to the surface of the nanoparticle, resulting in improved therapeutic properties such as efficacy, safety, and increased half-life in the blood for small molecule drugs (thereby allowing less frequent intravenous dosing).
Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014
Production of Biocompatible Polymers in Iran October 30th, 2014
Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014
'Electronic skin' could improve early breast cancer detection October 29th, 2014